Valeo Pharma Inc. coverage, "Big Pharma Capabilities" This article just came across my feed this PM; https://technologymarketwatch.com/vph.htm very good overview of Valeo.
Valeo Pharma Inc. -- Big Pharma Capabilities
Valeo Pharma Inc. (CSE: VPH) is a fully integrated specialty pharmaceutical company focused on in-licensing prescription drugs for the Canadian market. The Company acquires the Canadian rights from international drug manufacturers wanting access to the Canadian markets without the hassle. Valeo is not a developer of drugs (thus no big R&D expenditure and risk), it does everything that a big pharmaceutical company does after it develops a drug, to make it a commercial success. Valeo maintains, in-house, all the necessary capabilities and infrastructure to register and manage a drug through all stages of commercialization. Valeo focuses its efforts on commercial stage, innovative and proprietary drugs targeting three therapeutic areas; 1) Neurodegenerative diseases, 2) Oncology, and 3) Hospital Specialty Products. Valeo targets areas where it can be highly impactful marketing-wise with a limited/streamlined sales team (e.g. of the ~900 neurologists in Canada, less than 10% are the key initiators of initial prescriptions). The Company has recently added proprietary branded-products with significant growth potential that are expected to dramatically increase revenues. Its pipeline over the coming months and years should see additional robust growth as the Company's goal of becoming a dominant player in its targeted therapeutic fields is increasingly realized.
Shares of Valero Pharma Inc. trade on the Canadian Securities Exchange under the symbol VPH (began trading in February 2019). Looking at price-to-sales ratio metrics relative to the coming pipeline, shares of VPH are expected to experience solid price appreciation as revenue projections come to fruition, and certainly higher as news develops regarding additions to the pipeline.
Valeo is set to achieve breakeven this 2020, and accelerate revenue-wise from there; revenues are projected to go from ~$10M in 2020 to near $90M within a couple years based on the existing and fast growing product pipeline with the help of two recent product additions; 1) ONSTRYV®, the 1st Parkinson's Disease treatment launched in Canada since 2006 (now approved in Canada, marketing underway with access incrementally coming online), and 2) REDESCA®, a low molecular weight heparin biosimilar used to prevent deep vein thrombosis and pulmonary embolism (scheduled for approval in Canada in Fall 2020, with marketing beginning in early 2021)..... see full content here https://technologymarketwatch.com/vph.htm